Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease

Respiratory Research

Table 3 Change of lung function and SGRQ score over time by eosinophil stability

	Persistently < 300 (n = 175)	Variable (n = 68)	Persistently ≥300 (n = 56)
FEV₁, mL
Change of FEV_1, mL/year	− 29.71 (− 37.90, − 21.52)	− 18.48 (− 31.03, − 5.92)	− 28.15 (− 41.61, − 14.69)
Difference in change of FEV_1, mL/year	Reference	11.23 (− 3.76, 26.23)	1.56 (− 14.20, 17.32)
Adjusted^a change of FEV_1, mL/year	− 29.66 (− 37.92, − 21.41)	−18.42 (− 31.06, − 5.79)	− 28.15 (− 41.70, − 14.60)
Adjusted^a difference in change of FEV_1, mL/year	Reference	11.23 (− 3.86, 26.32)	1.50 (− 14.36, 17.36)
SGRQ score
Symptoms
Adjusted^b change of score /year	−0.22 (− 1.45, 1.01)	1.45 (− 0.34, 3.24)	−2.75 (− 4.77, − 0.73)
Adjusted^b difference in score /year	Reference	1.68 (−0.50, 3.85)	−2.53 (− 4.89, − 0.16)
Activity
Adjusted^b change of score /year	0.14 (−1.61, 1.88)	0.23 (− 2.36, 2.81)	−1.07 (− 3.91, 1.77)
Adjusted^b difference in score /year	Reference	0.09 (−3.03, 3.21)	−1.21 (− 4.54, 2.13)
Impact
Adjusted^b change of score /year	0.73 (−0.62, 2.07)	− 0.24 (− 2.22, 1.75)	−2.44 (− 4.63, − 0.25)
Adjusted^b difference in score /year	Reference	−0.97(− 3.36, 1.43)	− 3.17 (− 5.74, − 0.60)
Total
Adjusted^b change of score /year	0.26 (−1.15, 1.66)	0.14 (− 1.95, 2.24)	− 2.34 (− 4.63, − 0.04)
Adjusted^b difference in score /year	Reference	−0.11 (−2.64, 2.41)	− 2.59 (− 5.29, 0.09)

Abbreviations: SGRQ St George’s Respiratory Questionnaire, FEV₁ forced expiratory volume in 1 second
^aAdjusted for age, smoking status, self-reported history of asthma, two or more moderate exacerbations or one or more severe exacerbation during the previous year, and use of inhaled corticosteroids(ICS)/long-acting β₂-agonist or ICS for more than two thirds of the study period
^bAdjusted for age, smoking status, self-reported history of asthma, two or more moderate exacerbations or one or more severe exacerbation during the previous year, post-bronchodilator FEV₁ < 50% predicted at baseline, and use of inhaled corticosteroids (ICS)/long-acting β₂-agonist or ICS for more than two thirds of the study period

ISSN: 1465-993X